temsirolimus + pazopanib

A dual-agent combination of the mTOR inhibitor temsirolimus and the VEGFR tyrosine kinase inhibitor pazopanib investigated to achieve vertical pathway inhibition of angiogenesis and mTOR signaling in solid tumors, particularly renal cell carcinoma. Temsirolimus inhibits the mTOR pathway, reducing tumor cell growth, proliferation, and angiogenic signaling, while pazopanib inhibits VEGF receptors 1–3, platelet-derived growth factor receptors, and c-Kit to block angiogenesis. A phase I study found the combination was not feasible at clinically meaningful doses due to high rates of grade ≥3 toxicities, including constitutional symptoms and electrolyte disturbances, even at reduced doses (temsirolimus 10 mg IV weekly plus pazopanib 200 mg daily). This combination has not been approved and remains investigational as a pairing, with clinical use generally favoring single-agent therapy or other combinations in RCC.[1][3]

Other names

temsirolimus and pazopanib